Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial

American Heart Journal Jul 18, 2019

Sharma A, et al. - Given the risk for bleeding and subsequent adverse non–bleeding-related events among patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants, researchers assessed clinical events during a 30-day period after Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding. This post hoc analysis included 7,392 high-risk patients (median follow-up 241 days) with a recent ACS who were randomized to apixaban or placebo. During follow-up, TIMI major/minor bleeding was reported in 153 (2.1%) patients. They noted significantly increased risk of ensuing ischemic events and mortality in correlation to bleeding. This risk was noted irrespective of antithrombotic or anticoagulant strategy. Bleeding risk was comparable for patients receiving apixaban plus aspirin vs those receiving thienopyridine plus aspirin.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen